Total Payments
$87,475
2024 Payments
$1,024
Companies
51
Transactions
461
Medicare Patients
3,336
Medicare Billing
$385,869
Payment Breakdown by Category
Research$77,580 (88.7%)
Food & Beverage$8,278 (9.5%)
Other$1,500 (1.7%)
Education$116.96 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $77,580 | 33 | 88.7% |
| Food and Beverage | $8,278 | 419 | 9.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,500 | 1 | 1.7% |
| Education | $116.96 | 8 | 0.1% |
Payments by Type
Research
$77,580
33 transactions
General
$9,895
428 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Valneva Austria GmbH | $74,567 | 11 | $0 (2022) |
| Regeneron Pharmaceuticals, Inc. | $1,877 | 8 | $0 (2017) |
| PFIZER INC. | $1,669 | 10 | $0 (2024) |
| ABBVIE INC. | $1,625 | 92 | $0 (2024) |
| SANOFI US SERVICES INC. | $1,136 | 14 | $0 (2018) |
| AstraZeneca Pharmaceuticals LP | $1,036 | 59 | $0 (2024) |
| Novo Nordisk Inc | $862.62 | 50 | $0 (2024) |
| Amgen Inc. | $627.31 | 24 | $0 (2022) |
| Allergan, Inc. | $385.59 | 15 | $0 (2020) |
| Takeda Pharmaceuticals U.S.A., Inc. | $372.65 | 19 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,024 | 43 | ABBVIE INC. ($285.56) |
| 2023 | $1,123 | 58 | ABBVIE INC. ($383.09) |
| 2022 | $76,299 | 96 | Valneva Austria GmbH ($74,567) |
| 2021 | $963.81 | 52 | AbbVie Inc. ($412.26) |
| 2020 | $537.73 | 29 | Allergan, Inc. ($129.88) |
| 2019 | $1,233 | 62 | Allergan Inc. ($255.71) |
| 2018 | $3,767 | 77 | PFIZER INC. ($1,500) |
| 2017 | $2,527 | 44 | Regeneron Pharmaceuticals, Inc. ($1,877) |
All Payment Transactions
461 individual payment records from CMS Open Payments — Page 1 of 19
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/27/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $25.93 | General |
| Category: NEUROSCIENCE | ||||||
| 11/19/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $14.74 | General |
| Category: Respiratory | ||||||
| 11/15/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $15.15 | General |
| Category: Diabetes Care | ||||||
| 11/14/2024 | CSL Behring | Hizentra (Biological) | Food and Beverage | In-kind items and services | $25.24 | General |
| Category: Immunology | ||||||
| 11/12/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $25.64 | General |
| Category: Diabetes | ||||||
| 10/31/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $28.04 | General |
| Category: Obesity | ||||||
| 10/29/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $27.62 | General |
| Category: NEUROSCIENCE | ||||||
| 10/29/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $25.48 | General |
| Category: NEUROSCIENCE | ||||||
| 10/29/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $4.33 | General |
| Category: NEUROSCIENCE | ||||||
| 10/24/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $26.84 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/22/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $34.14 | General |
| Category: NEUROSCIENCE | ||||||
| 10/19/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $3.70 | General |
| Category: NEUROSCIENCE | ||||||
| 10/08/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $18.42 | General |
| Category: Respiratory | ||||||
| 09/23/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $14.50 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/18/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $19.42 | General |
| Category: Gastroenterology | ||||||
| 08/20/2024 | Exact Sciences Corporation | Cologuard Collection Kit (Device) | Food and Beverage | In-kind items and services | $27.11 | General |
| Category: Oncology | ||||||
| 08/15/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $14.93 | General |
| Category: Respiratory | ||||||
| 08/12/2024 | PFIZER INC. | ELIQUIS (Drug), NURTEC ODT | Food and Beverage | In-kind items and services | $22.89 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 08/06/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $20.05 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 07/29/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $22.24 | General |
| Category: Obesity | ||||||
| 07/18/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $11.58 | General |
| Category: Respiratory | ||||||
| 07/15/2024 | CSL Behring | Hizentra (Biological) | Food and Beverage | In-kind items and services | $22.30 | General |
| Category: Immunology | ||||||
| 06/06/2024 | Exact Sciences Corporation | Cologuard Collection Kit (Device) | Food and Beverage | In-kind items and services | $34.36 | General |
| Category: Oncology | ||||||
| 05/30/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $18.73 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 05/29/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $23.20 | General |
| Category: Gastroenterology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| SAFETY AND IMMUNOGENICITY STUDY OF VLA15, A MULTIVALENT RECOMBINANT OSPA BASED VACCINE CANDIDATE AGAINST LYME BORRELIOSIS: A RANDOMIZED, CONTROLLED, OBSERVER-BLIND PHASE 2 STUDY IN A HEALTHY PEDIATRIC AND ADULT STUDY POPULATION. | Valneva Austria GmbH | $72,295 | 9 |
| Alternative schedule study for VLA15, a MULTIVALENT recombinant OspA BASED vaccine CANDIDATE against Lyme borreliosis, IN HEALTHY ADULTS AGED 18 to 65 years - a Randomized, controlled, observer-blind phase 2 study. | Valneva Austria GmbH | $2,272 | 2 |
| Phase 3 Randomized, Double-Blind, Multi-Dose, Placebo And NSAID Controlled Study To Evaluate The Efficacy And Safety Of Fasinumab In Patients With Pain Due To Osteoarthritis Of The Knee Or Hip | Regeneron Pharmaceuticals, Inc. | $1,877 | 8 |
| A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Sarilumab in Patients With Giant Cell Arteritis | SANOFI US SERVICES INC. | $1,136 | 14 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 18 | 974 | 1,716 | $175,775 | $107,633 |
| 2022 | 14 | 874 | 1,637 | $161,225 | $101,235 |
| 2021 | 12 | 786 | 1,782 | $165,605 | $91,957 |
| 2020 | 11 | 702 | 1,760 | $149,015 | $85,044 |
Total Patients
3,336
Total Services
6,895
Medicare Billing
$385,869
Procedure Codes
55
All Medicare Procedures & Services
55 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 152 | 367 | $55,050 | $35,008 | 63.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 120 | 295 | $32,710 | $18,577 | 56.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 75 | 85 | $18,485 | $11,283 | 61.0% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 82 | 82 | $16,400 | $11,137 | 67.9% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 34 | 217 | $16,275 | $10,696 | 65.7% |
| 96132 | Evaluation of neuropsychological test, first hour | Office | 2023 | 48 | 51 | $8,925 | $5,163 | 57.8% |
| 99496 | Transitional care management services for problem of high complexity | Office | 2023 | 14 | 17 | $6,205 | $3,959 | 63.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 13 | 13 | $3,900 | $2,383 | 61.1% |
| G0444 | Annual depression screening, 5 to 15 minutes | Office | 2023 | 81 | 81 | $2,430 | $1,595 | 65.6% |
| G0442 | Annual alcohol misuse screening, 5 to 15 minutes | Office | 2023 | 80 | 80 | $2,400 | $1,575 | 65.6% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 118 | 183 | $1,745 | $1,502 | 86.0% |
| 96138 | Administration of psychological or neuropsychological test by technician, first 30 minutes | Office | 2023 | 48 | 51 | $3,570 | $1,339 | 37.5% |
| G0446 | Annual, face-to-face intensive behavioral therapy for cardiovascular disease, individual, 15 minutes | Office | 2023 | 46 | 46 | $1,770 | $1,245 | 70.3% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 12 | 14 | $1,550 | $708.68 | 45.7% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 11 | 18 | $1,335 | $691.18 | 51.8% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 12 | 43 | $1,290 | $458.65 | 35.6% |
| 36410 | Insertion of needle into vein (3 years or older) | Office | 2023 | 17 | 22 | $550.00 | $252.79 | 46.0% |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 2023 | 11 | 51 | $1,185 | $58.79 | 5.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 124 | 255 | $38,250 | $25,490 | 66.6% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2022 | 52 | 431 | $29,775 | $20,572 | 69.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 110 | 242 | $30,170 | $17,317 | 57.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 86 | 110 | $24,620 | $14,873 | 60.4% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 64 | 64 | $12,800 | $8,963 | 70.0% |
| 96132 | Evaluation of neuropsychological test, first hour | Office | 2022 | 50 | 58 | $10,375 | $6,282 | 60.6% |
| G0446 | Annual, face-to-face intensive behavioral therapy for cardiovascular disease, individual, 15 minutes | Office | 2022 | 61 | 61 | $2,620 | $1,703 | 65.0% |
About Dr. David Radin, MD
Dr. David Radin, MD is a Internal Medicine healthcare provider based in Stamford, Connecticut. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/03/2006. The National Provider Identifier (NPI) number assigned to this provider is 1225076193.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Radin, MD has received a total of $87,475 in payments from pharmaceutical and medical device companies, with $1,024 received in 2024. These payments were reported across 461 transactions from 51 companies. The most common payment nature is "" ($77,580).
As a Medicare-enrolled provider, Radin has provided services to 3,336 Medicare beneficiaries, totaling 6,895 services with total Medicare billing of $385,869. Data is available for 4 years (2020–2023), covering 55 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location Stamford, CT
- Active Since 06/03/2006
- Last Updated 09/18/2023
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1225076193
Products in Payments
- KEVZARA (Drug) $1,136
- VRAYLAR (Drug) $900.78
- UBRELVY (Drug) $577.20
- FARXIGA (Drug) $572.97
- Ozempic (Drug) $512.38
- BREZTRI (Drug) $260.17
- Prolia (Biological) $252.80
- TRINTELLIX (Drug) $252.37
- Hizentra (Biological) $231.05
- QULIPTA (Drug) $223.50
- Saxenda (Drug) $217.33
- ENTRESTO (Drug) $212.82
- JARDIANCE (Drug) $208.03
- XIFAXAN (Drug) $206.49
- JANUVIA (Drug) $188.50
- Cologuard Collection Kit (Device) $172.26
- EVENITY (Biological) $158.70
- GEMTESA (Drug) $137.90
- Trintellix (Drug) $133.37
- VOQUEZNA (Drug) $124.05
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Stamford
Scott Gottlieb, Md, MD
Internal Medicine — Payments: $394,103
Internal Medicine $394,103
Dr. Gavin Mcleod, Md, MD
Internal Medicine — Payments: $32,723
Internal Medicine $32,723
Dr. Antonios Katsigiannis, M.d, M.D
Internal Medicine — Payments: $27,959
Internal Medicine $27,959
Dr. Brian Wojeck, M.d. M. P.h, M.D. M. P.H
Internal Medicine — Payments: $10,928
Internal Medicine $10,928
Dr. Amy Smithline, Md, MD
Internal Medicine — Payments: $10,471
Internal Medicine $10,471
Estela Rodriguez Alonso, Md, MD
Internal Medicine — Payments: $8,970
Internal Medicine $8,970